Abstract library

6 results for "Sorby".
#314 Clinical Effect of Temozolomide-Based Chemotherapy in Poorly Differentiated Endocrine Carcinoma (PDEC) after Progression on First-Line Chemotherapy
Introduction: Patients with metastatic PDEC usually have a short survival. After first-line palliative chemotherapy, there are no established second-line treatments. Temozolomide has shown effect in other NETs.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Staffan Welin
Authors:
#1455 Expression of Mutated p53 Protein in Gastroenteropancreatic Neuroendocrine Carcinoma (WHO G3)
Introduction: Gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs) are aggressive, highly proliferating tumors. Therapeutic response to current chemotherapy regimens is usually short-lasting.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: PhD student Abeir Ali
Authors:
#1604 Resection of Liver Metastases in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Carcinomas: A Nordic Multicenter Study
Introduction: Gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) are generally characterized by synchronous metastases, high aggressiveness and a dismal prognosis. Currently, resection of liver metastases in patients with metastatic GEP-NEC is not recommended. However, the existing data are scarce.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: MD Renate Berget Galleberg
Authors:
#1694 Plasma Protein Fingerprinting for the Diagnosis of Small Intestinal Neuroendocrine Tumors (siNETs)
Introduction: siNETs are notoriously difficult to diagnose, especially in an early stage.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: MD PhD Magnus Kjellman
Authors:
#1783 Gastroenteropancreatic High-Grade Neuroendocrine Carcinomas: A SEER Database Analysis of 6291 Cases
Introduction: Knowledge about gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) is scarce given their low incidence rates and aggressive clinical behavior
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Arvind Dasari
Authors:
Keywords: Grade 3, NE carcinoma
#2072 Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic Grade 3 Neuroendocrine Neoplasms: A Retrospective International Multicenter Study
Introduction: Gastroenteropancreatic (GEP) grade 3 neuroendocrine neoplasms (NEN G3) are rare, highly malignant neoplasms with poor prognosis and limited therapeutic options. Median survival following chemotherapy is only 10-12 months.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MD, PhD Dorthe Skovgaard
Authors: